Extended Data Fig. 9: Increases in sAXL following cabozantinib treatment in Nf1flox/flox;PostnCre mice.
From: Cabozantinib for neurofibromatosis type 1–related plexiform neurofibromas: a phase 2 trial
a, Cartoon schematic depicting release of soluble AXL following binding of Gas6 and proteolytic cleavage. b, Soluble AXL was measured by ELISA in the plasma of WT (PostnCre negative) (n = 8) and Nf1flox/flox;PostnCre mice following 12 weeks of treatment with either vehicle (n = 13) or cabozantinib (n = 16). *Adjusted P-value = 0.0167 WT vs cabozantinib Nf1flox/flox;PostnCre, *Adjusted P-value = 0.0179 vehicle vs cabozantinib Nf1flox/flox;PostnCre (one-way ANOVA with Tukey’s multiple comparisons test).
